BR112019006227A2 - métodos de tratamento de leiomioma uterino e endometriose - Google Patents
métodos de tratamento de leiomioma uterino e endometrioseInfo
- Publication number
- BR112019006227A2 BR112019006227A2 BR112019006227A BR112019006227A BR112019006227A2 BR 112019006227 A2 BR112019006227 A2 BR 112019006227A2 BR 112019006227 A BR112019006227 A BR 112019006227A BR 112019006227 A BR112019006227 A BR 112019006227A BR 112019006227 A2 BR112019006227 A2 BR 112019006227A2
- Authority
- BR
- Brazil
- Prior art keywords
- subject
- methods
- endometriosis
- uterine leiomyoma
- adenomyosis
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title abstract 4
- 206010046798 Uterine leiomyoma Diseases 0.000 title abstract 4
- 201000010260 leiomyoma Diseases 0.000 title abstract 4
- 201000007954 uterine fibroid Diseases 0.000 title abstract 4
- 208000005641 Adenomyosis Diseases 0.000 abstract 3
- 201000009274 endometriosis of uterus Diseases 0.000 abstract 3
- 208000024891 symptom Diseases 0.000 abstract 3
- 230000000740 bleeding effect Effects 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 2
- 239000011707 mineral Substances 0.000 abstract 2
- -1 4- (1- (2,6-difluorobenzyl ) -5 - ((dimethylamino) methyl) -3- (6-methoxy-3-pyridazinyl) -2,4-dioxo-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidin-6-yl ) phenyl Chemical group 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 208000033830 Hot Flashes Diseases 0.000 abstract 1
- 206010060800 Hot flush Diseases 0.000 abstract 1
- 206010046788 Uterine haemorrhage Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 1
- 239000002474 gonadorelin antagonist Substances 0.000 abstract 1
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 208000000509 infertility Diseases 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 231100000535 infertility Toxicity 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 208000007106 menorrhagia Diseases 0.000 abstract 1
- 230000002175 menstrual effect Effects 0.000 abstract 1
- 230000003821 menstrual periods Effects 0.000 abstract 1
- 230000001457 vasomotor Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Surgical Instruments (AREA)
Abstract
métodos para tratamento de leiomioma uterino, endometriose, adenomiose, ou sangramento menstrual intenso em um sujeito, que incluem a administração, ao sujeito, de 10 mg a 60 mg por dia de n-(4-(1-(2,6-difluorobenzil)-5-((dimetilamino)metil)-3-(6-metoxi-3-piridazinil)-2,4-dioxo-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-il)fenil)-n'-metoxiureia, e de 0,01 mg a 5 mg por dia de um medicamento de reposição hormonal. a presente divulgação apresenta métodos para reduzir o sangramento menstrual em um sujeito, reduzir a perda de densidade mineral óssea em um sujeito causada pela administração de um antagonista de gnrh ao sujeito, suprimir os hormônios sexuais em um sujeito, reduzir os sintomas vasomotores ou fogachos em um sujeito, e reduzir os sintomas de libido reduzida em um sujeito com leiomioma uterino, endometriose ou adenomiose. são fornecidos ainda métodos de manutenção do perfil de glicose sanguínea, manutenção do perfil lipídico e/ou manutenção da densidade mineral óssea em uma mulher na pré-menopausa sendo tratada para uma ou mais condições ou sintomas de endometriose, adenomiose, leiomioma uterino, ou sangramento menstrual intenso; e métodos de contracepção e tratamento de infertilidade.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402055P | 2016-09-30 | 2016-09-30 | |
| US201662402034P | 2016-09-30 | 2016-09-30 | |
| US201662402150P | 2016-09-30 | 2016-09-30 | |
| US201762492839P | 2017-05-01 | 2017-05-01 | |
| US201762528409P | 2017-07-03 | 2017-07-03 | |
| PCT/EP2017/074907 WO2018060501A2 (en) | 2016-09-30 | 2017-09-29 | Methods of treating uterine fibroids and endometriosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019006227A2 true BR112019006227A2 (pt) | 2019-06-18 |
Family
ID=60915460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019006227A BR112019006227A2 (pt) | 2016-09-30 | 2017-09-29 | métodos de tratamento de leiomioma uterino e endometriose |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11033551B2 (pt) |
| EP (2) | EP4094766A1 (pt) |
| JP (1) | JP7043503B2 (pt) |
| CN (1) | CN110312512B (pt) |
| AU (2) | AU2017336363B2 (pt) |
| BR (1) | BR112019006227A2 (pt) |
| CA (1) | CA3038879A1 (pt) |
| CY (1) | CY1125254T1 (pt) |
| DK (1) | DK3518933T3 (pt) |
| ES (1) | ES2912929T3 (pt) |
| HR (1) | HRP20220708T1 (pt) |
| HU (1) | HUE059101T2 (pt) |
| IL (2) | IL300580A (pt) |
| LT (1) | LT3518933T (pt) |
| MD (1) | MD3518933T2 (pt) |
| MX (1) | MX2019003726A (pt) |
| NZ (1) | NZ752916A (pt) |
| PL (1) | PL3518933T3 (pt) |
| PT (1) | PT3518933T (pt) |
| RS (1) | RS63300B1 (pt) |
| SI (1) | SI3518933T1 (pt) |
| WO (1) | WO2018060501A2 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7062673B2 (ja) | 2016-09-30 | 2022-05-06 | ミオバント サイエンシズ ゲーエムベーハー | 前立腺がんの治療 |
| PT3518933T (pt) | 2016-09-30 | 2022-05-10 | Takeda Pharmaceuticals Co | Métodos de tratamento de fibroides uterinos e endometriose |
| JP7292566B2 (ja) | 2017-06-05 | 2023-06-19 | キッセイ薬品工業株式会社 | 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 |
| EA201992612A1 (ru) | 2017-06-05 | 2020-05-20 | Обсева С.А. | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза |
| WO2019203870A1 (en) * | 2018-04-19 | 2019-10-24 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
| US20220117969A1 (en) * | 2018-10-29 | 2022-04-21 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| RU2711658C1 (ru) * | 2019-04-16 | 2020-01-20 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Способ лечения наружного генитального эндометриоза |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| JP2022543308A (ja) * | 2019-08-08 | 2022-10-11 | オブセヴァ エス．エー． | エストロゲン依存性障害の治療のための組成物及び方法 |
| EP4041738A1 (en) * | 2019-10-10 | 2022-08-17 | Myovant Sciences GmbH | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| WO2021069711A1 (en) * | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea |
| CN113384581B (zh) * | 2020-03-12 | 2023-11-14 | 成都倍特药业股份有限公司 | 一种包含促性腺激素释放激素拮抗剂的药物组合物 |
| CN115666531A (zh) | 2020-05-29 | 2023-01-31 | 梦欧文科学有限责任公司 | 促性腺激素释放激素拮抗剂的组合固体口服剂型 |
| EP4243829A1 (en) | 2020-11-11 | 2023-09-20 | Myovant Sciences GmbH | Methods of administering relugolix |
| WO2023066941A1 (en) | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| WO2024015934A2 (en) * | 2022-07-13 | 2024-01-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of diagnostic screening and early detection of adenomyosis |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US402034A (en) | 1889-04-23 | Dumping-wagon | ||
| US402150A (en) | 1889-04-30 | Broadcast seed-sower | ||
| US528409A (en) | 1894-10-30 | Denis ahern | ||
| US402055A (en) | 1889-04-23 | Water-motor | ||
| US492839A (en) | 1893-03-07 | Key for brake-shoes | ||
| FR2512732A1 (fr) | 1981-09-14 | 1983-03-18 | Raffinage Cie Francaise | Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications |
| US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| ECSP961635A (es) | 1996-01-11 | 1997-06-27 | Desprendimiento controlado de esteroides del recubrimiento de azucar | |
| ECSP971998A (es) | 1997-01-15 | 1998-04-07 | Desprendimiento controlado de esteroides del recubrimiento de azucar | |
| DE19815060A1 (de) | 1998-04-03 | 1999-10-14 | Jenapharm Gmbh | Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie |
| US6265393B1 (en) * | 1998-08-07 | 2001-07-24 | Heinrichs William Leroy | Prevention of endometriosis signs or symptons |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| RU2233284C2 (ru) | 1999-03-24 | 2004-07-27 | Такеда Кемикал Индастриз, Лтд. | Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона |
| EP1266898A4 (en) | 2000-02-29 | 2003-05-21 | Takeda Chemical Industries Ltd | PROCESSES FOR PRODUCING THIENOPYRAMIDINE DERIVATIVES |
| EP1479684A4 (en) | 2002-01-30 | 2006-01-04 | Takeda Pharmaceutical | THIENOPYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE |
| CN100360538C (zh) | 2003-01-29 | 2008-01-09 | 武田药品工业株式会社 | 噻吩并嘧啶化合物及其用途 |
| SI1646389T1 (sl) | 2003-07-07 | 2009-02-28 | Neurocrine Biosciences Inc | Derivati pirimidin-2,4-diona kot antagonisti receptorja gonadotropin sproĺ äśajoäśega hormona |
| MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| ZA200801150B (en) | 2005-07-22 | 2010-05-26 | Takeda Pharmaceutical | Premature ovulation preventive agent |
| AR058584A1 (es) | 2005-12-22 | 2008-02-13 | Takeda Pharmaceutical | Derivados de metastina y uso de los mismos |
| CN101678007B (zh) | 2007-04-06 | 2013-07-03 | 纽罗克里生物科学有限公司 | 促性腺激素释放激素受体拮抗剂及其制药用途 |
| WO2009062087A1 (en) | 2007-11-07 | 2009-05-14 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| EP2329823A4 (en) | 2008-09-03 | 2013-04-03 | Takeda Pharmaceutical | METHOD FOR IMPROVING CAPACITY OF PREPARATION TO BE ABSORBED AND PREPARATION WHICH CAPACITY TO BE ABSORBED IS IMPROVED |
| US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| CA2802761C (en) | 2010-06-16 | 2017-01-03 | Endorecherche, Inc. | Methods of treating or preventing estrogen-related diseases |
| JP2012077020A (ja) | 2010-09-30 | 2012-04-19 | Mochida Pharmaceut Co Ltd | ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬 |
| EP4119564A1 (en) | 2012-09-28 | 2023-01-18 | Takeda Pharmaceutical Company Limited | Production method of thienopyrimidine derivative |
| EP2968566A1 (en) * | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Compositions for use in treating heavy menstrual bleeding and uterine fibroids |
| EP4233847A1 (en) | 2015-02-26 | 2023-08-30 | Takeda Pharmaceutical Company Limited | A tablet comprising a methoxyurea derivative and mannitol particles |
| CA3002791A1 (en) | 2015-09-01 | 2017-03-09 | Abbvie Inc. | Methods of administering elagolix |
| JP7062673B2 (ja) | 2016-09-30 | 2022-05-06 | ミオバント サイエンシズ ゲーエムベーハー | 前立腺がんの治療 |
| PT3518933T (pt) | 2016-09-30 | 2022-05-10 | Takeda Pharmaceuticals Co | Métodos de tratamento de fibroides uterinos e endometriose |
| EA201992612A1 (ru) | 2017-06-05 | 2020-05-20 | Обсева С.А. | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза |
| WO2021069711A1 (en) | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea |
| EP4041738A1 (en) | 2019-10-10 | 2022-08-17 | Myovant Sciences GmbH | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| CN115666531A (zh) | 2020-05-29 | 2023-01-31 | 梦欧文科学有限责任公司 | 促性腺激素释放激素拮抗剂的组合固体口服剂型 |
| EP4243829A1 (en) | 2020-11-11 | 2023-09-20 | Myovant Sciences GmbH | Methods of administering relugolix |
| WO2023066941A1 (en) | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
-
2017
- 2017-09-29 PT PT178230181T patent/PT3518933T/pt unknown
- 2017-09-29 CA CA3038879A patent/CA3038879A1/en active Pending
- 2017-09-29 MX MX2019003726A patent/MX2019003726A/es unknown
- 2017-09-29 JP JP2019538721A patent/JP7043503B2/ja active Active
- 2017-09-29 PL PL17823018T patent/PL3518933T3/pl unknown
- 2017-09-29 HU HUE17823018A patent/HUE059101T2/hu unknown
- 2017-09-29 ES ES17823018T patent/ES2912929T3/es active Active
- 2017-09-29 WO PCT/EP2017/074907 patent/WO2018060501A2/en active Application Filing
- 2017-09-29 AU AU2017336363A patent/AU2017336363B2/en active Active
- 2017-09-29 EP EP22162349.9A patent/EP4094766A1/en active Pending
- 2017-09-29 RS RS20220565A patent/RS63300B1/sr unknown
- 2017-09-29 CN CN201780072987.XA patent/CN110312512B/zh active Active
- 2017-09-29 EP EP17823018.1A patent/EP3518933B1/en active Active
- 2017-09-29 BR BR112019006227A patent/BR112019006227A2/pt unknown
- 2017-09-29 SI SI201731123T patent/SI3518933T1/sl unknown
- 2017-09-29 DK DK17823018.1T patent/DK3518933T3/da active
- 2017-09-29 LT LTEPPCT/EP2017/074907T patent/LT3518933T/lt unknown
- 2017-09-29 MD MDE20190880T patent/MD3518933T2/ro unknown
- 2017-09-29 IL IL300580A patent/IL300580A/en unknown
- 2017-09-29 NZ NZ752916A patent/NZ752916A/en unknown
- 2017-09-29 HR HRP20220708TT patent/HRP20220708T1/hr unknown
-
2019
- 2019-03-28 IL IL265700A patent/IL265700B2/en unknown
- 2019-03-29 US US16/370,299 patent/US11033551B2/en active Active
-
2021
- 2021-05-11 US US17/317,769 patent/US11793812B2/en active Active
-
2022
- 2022-06-02 CY CY20221100390T patent/CY1125254T1/el unknown
- 2022-07-15 US US17/866,201 patent/US11957684B2/en active Active
- 2022-09-30 AU AU2022241582A patent/AU2022241582A1/en active Pending
-
2024
- 2024-01-30 US US18/427,579 patent/US20240165118A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019006227A2 (pt) | métodos de tratamento de leiomioma uterino e endometriose | |
| AR065179A1 (es) | Progesterona para el tratamiento o prevencion del parto prematuro espontaneo | |
| JP2017039771A5 (pt) | ||
| CO6630125A2 (es) | Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometriosis | |
| MX2019011530A (es) | Saxitoxinas 11,13-modificadas para el tratamiento del dolor. | |
| MX2021006575A (es) | Composiciones y metodos para el tratamiento de trastornos del higado. | |
| PE20211588A1 (es) | Compuestos y sus usos para aliviar sintomas asociados a la menopausia | |
| MX2021002321A (es) | Nuevos metodos. | |
| EA201791361A1 (ru) | Терапия антагонистом рецепторов окситоцина в лютеиновую фазу для имплантации и беременности у женщин, проходящих процедуры вспомогательных репродуктивных технологий | |
| MX369518B (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
| MX2017014844A (es) | Regimen modulador selectivo de los receptores de progesterona (sprm). | |
| CO7111317A2 (es) | Método para el tratamiento de enfermedades ginecológicas | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| DK1879572T3 (da) | Anvendelse af antagonister af oxytocin og/eller vasopressin i kunstig befrugtning | |
| CL2015003014A1 (es) | Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas. | |
| EA201990857A1 (ru) | Способы лечения миомы матки и эндометриоза | |
| BR112015009504A2 (pt) | inibidores de rock | |
| BR112022001645A2 (pt) | Artigo configurado para liberação de um agente terapêutico, e, métodos para distribuir fármaco intestinal e para administrar um agente terapêutico | |
| Mishra et al. | Role of micronised progesterone in maintenance therapy following arrested preterm labor: a randomised controlled trial | |
| MX2019000498A (es) | Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos. | |
| MA46362B1 (fr) | Méthodes de traitement des fibromes utérins et de l'endométriose | |
| EA202090163A1 (ru) | Средство для лечения женского бесплодия и бесплодия самок животных | |
| BR112015008681A2 (pt) | combinação | |
| Veras et al. | Effect of eCG and FSH in ovulation rate, size of corpus luteum and conception rate in heifers 5/8 Girolando undergoing fixed time artificial insemination. | |
| Rashidi et al. | Evaluation of the Endometrial Thickness in Mice after Ovarian Stimulation and Using Progesterone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) ; MYOVANT SCIENCES GMBH (CH) |